CN2426361Y - Mixed biologic artificial liver supporting device - Google Patents
Mixed biologic artificial liver supporting device Download PDFInfo
- Publication number
- CN2426361Y CN2426361Y CN 00223561 CN00223561U CN2426361Y CN 2426361 Y CN2426361 Y CN 2426361Y CN 00223561 CN00223561 CN 00223561 CN 00223561 U CN00223561 U CN 00223561U CN 2426361 Y CN2426361 Y CN 2426361Y
- Authority
- CN
- China
- Prior art keywords
- blood plasma
- blood
- communicated
- pond
- liquid pipe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- External Artificial Organs (AREA)
Abstract
The utility model relates to a mixed biologic artificial liver supporting device, composed of a module control circuit, a blood plasma separation mechanism, a blood plasma adsorption mechanism, a biologic response mechanism, a blood plasma output mechanism, an incubator, a blood plasma tank, etc. On the basis of the reservation of more beneficial substances in the blood, the utility model detoxicates the blood plasma on physical property and converts metabolism on toxic substances in the blood plasma through high activity incubating liver cells to thoroughly detoxicate the liver. More importantly, the utility model can provide a great amount of biologic active substances synthesized and secreted by incubating liver cells for the patient when the liver is insufficient.
Description
This utility model relates to a kind of armarium, the artificial hepaticsupport system that particularly a kind of temporary replacement human liver is hidden.
Existing artificial hepaticsupport system generally is divided into blood absorbent-type artificial hepaticsupport system and plasmapheresis type artificial hepaticsupport system.Blood absorbent-type artificial hepaticsupport system is made of adsorber, blood pump and liquid pipe; It belongs to artificial liver the earliest, during use, its input port and delivery outlet all is communicated with patient's blood vessel, utilizes the absorbent charcoal material in adsorber with physical form the toxic component in the blood to be carried out adsorption cleaning, reaches liver antidotal purpose; Because adsorbing material poor selectivity, and the histocompatibility of material own is relatively poor, in adsorption process, though it can be removed the absorption of the noxious substance in the blood, but it also together adsorbs many materials to the human body beneficial in the blood and removes, cause the particularly hematoblastic minimizing of hemocyte in the blood, therefore, curative effect can not be satisfactory after the clinical practice.Plasmapheresis type artificial hepaticsupport system belongs to the artificial liver that the second filial generation has certain liver function, and it mainly is to be made of separator, blood pump and liquid pipe; During use, its input port and delivery outlet all are communicated with patient's blood vessel, by separator the separating plasma in the blood is come out, and contain toxicant and the blood plasma of human body beneficial's material is together abandoned this, blood plasma with the normal person injects in patient's body again, thereby patient's blood is purified, realizes liver antidotal purpose; The place that this device is better than aforementioned means is exactly also to replenish the required albumin of certain biotic component such as normal person, thrombin etc. when removing toxicant, therefore be a kind of middle type technology between physical and Biotype artificial liver, it still will abandon many materials to the human body beneficial in the blood plasma, to consume a large amount of normal persons' blood plasma simultaneously, cause many wastes.In a word, with regard to Detoxication, above-mentioned two kinds of devices exist maximum defectives all be remove indiscriminately in the blood samples of patients noxious substance and to human body beneficial's material, can not can be regarded as artificial liver truly, just have to a certain extent mechanicalness Detoxication and the artificial effect that replenishes plasma fraction respectively.
The purpose of this utility model just provides a kind of mixed biologic artificial hepaticsupport system simple in structure and easy to use, it can keep in the blood on the basis to human body beneficial's material more, only need to use a spot of human normal plasma, utilize active carbon that blood plasma is carried out the adsorption-type detoxifcation, and cultivate hepatocyte by the high activity of artificial culture the toxicant in patient's blood plasma is absorbed absorption, transforms metabolism, realize the liver detoxifcation for a full due.
The purpose of this utility model is to realize by such technical scheme, it includes housing and module control circuit, it is characterized in that: it also includes input channel, detaching mechanism of blood plasma, the blood plasma adsorbing mechanism, biological respinse mechanism, blood plasma output mechanism and output channel, be provided with the blood plasma pond in the intravital incubator of shell, biological respinse mechanism and blood plasma adsorbing mechanism form internal recycle with the blood plasma pond respectively, the blood plasma outfan of the detaching mechanism of blood plasma that input is communicated with input channel is by the liquid pipe, the liquid pipe valve feeds blood plasma pond and useless blood plasma container respectively, the blood plasma output mechanism that is communicated with the blood plasma pond by by the Meng Fei Shi pipe be communicated with output channel.
This utility model is external artificial hepaticsupport system, does not insert in patient's body, but blood samples of patients is drawn, and after the processing through the difference in functionality effect, converges and flows back in patient's body, so repeatedly, finally reaches the effect of artificial liver support and replacement therapy.Its operation principle is described below:
Input channel of the present utility model is communicated with patient's tremulous pulse or vein by puncture, output channel is communicated with patient's vein by puncture, to realize the connection of bloody path.
At first, be separated into blood samples of patients invisible and blood plasma that have toxicant and tangible blood concentration components by detaching mechanism of blood plasma, control liquid pipe valve, make the blood plasma that has toxicant through the blood plasma outfan, the liquid pipe is transported in the useless blood plasma container and it is abandoned, the blood concentration components is through blood concentration components outfan, the Meng, Fei Shi managed, output channel flows back in patient's body, simultaneously, under the effect of module control circuit, by blood plasma output mechanism and blood exchange transfusion set in patient's body, to inject normal person's blood plasma with the same speed of the toxic material blood plasma of blood plasma outfan elution band, this process is carried out repeatedly, the blood plasma that has toxicant in useless blood plasma container reaches till institute's plasma volume to be processed, this is the treatment of first step artificial liver, its objective is that the blood plasma that patient's body is contained more toxicant discards, in patient's body, mend normal person's blood plasma, realize detoxifcation and purification blood.
Continuation is separated into blood samples of patients invisible and blood plasma that have toxicant and tangible blood concentration components by detaching mechanism of blood plasma, control liquid pipe valve, make the blood plasma that has toxicant through the blood plasma outfan, the liquid pipe is transported in the blood plasma pond, the blood concentration components is still through blood concentration components outfan, the Meng, Fei Shi managed, output channel flows back in patient's body, when treating that blood plasma in the blood plasma pond reach a certain height, start the blood plasma output mechanism, with the blood plasma in the blood plasma pond through the blood plasma output mechanism, the Meng, Fei Shi managed, output channel to be failing back in patient's body with the same speed of the toxic material blood plasma of blood plasma outfan elution band, thereby realizes balance between patient's body inner blood and the device outside and stable circulating.
Secondly, having the blood plasma of toxicant and blood plasma adsorbing mechanism in the blood plasma pond carries out high speed and circulates, the blood plasma adsorbing mechanism with suction dehematize the slurry in most harmful substances, till the adsorbance of blood plasma adsorbing mechanism reaches capacity, thereby realize the physical property detoxifcation to blood plasma, this is the artificial liver treatment of second step.In this process, the blood plasma adsorbing mechanism has also been inhaled in the blood plasma material to the human body beneficial, and this deficiency can be remedied in bioartificial liver's treatment in the 3rd step fully.
The blood plasma of handling through above-mentioned detoxifcation in the blood plasma pond carries out high speed with biological respinse mechanism again and circulates, cultivate in the biological respinse mechanism a large amount of highly active cultivation hepatocyte are arranged, when blood plasma passes through biological respinse mechanism, highly active cultivation hepatocyte carries out specific picked-up to the toxicant in the blood plasma, conversion, metabolism, the large number of biological of synthesis secretion release simultaneously active substance enters blood plasma, so repeatedly, patient's blood plasma is carrying out the antidotal while for a full due in the mode of biology, replenish the large number of biological active substance of needed by human body again, thereby finished the 3rd step bioartificial liver treatment.
In sum, this utility model is as introducing blood samples of patients in external second liver, finishes the physiological function of the liver of loss of function in patient's body, Here it is mixed biologic artificial liver supporting treatment or alternative medicine by external this utility model.By therapeutical effect of the present utility model, the patient can recover by self liver regeneration, or recovers as liver transplantation through other treatment.This utility model creates conditions for above-mentioned liver regeneration or liver transplantation etc. just, races against time and chance, and be a kind of effective and requisite treatment means of excessive property, it has great importance aspect redemption liver failure patient life.
Owing to adopted technique scheme, the utlity model has following advantage:
1. simple in structure, easy to use, reliable;
2. the blood plasma adsorbing mechanism only carries out the detoxification processing to patient's blood plasma, has protected the visible component in the blood samples of patients, has eliminated any influence to hemocyte;
3. though the blood plasma adsorbing mechanism has still been removed in the blood plasma material to the human body beneficial, this defective is cultivated hepatocyte by the high activity of the artificial culture in the biological respinse mechanism and is released in the blood plasma by synthesis secretion and is remedied fully;
4. cultivate hepatocyte by the high activity of artificial culture in the biological respinse mechanism, toxicant in the blood plasma is absorbed absorption, transforms metabolism, thereby realize liver detoxifcation truly for a full due, and for the patient provides a large amount of by that cultivate the hepatocyte synthesis secretion and very deficient by the synthetic bioactive substance of liver when being liver failure, make it possess the basic function of normal liver fully by biological respinse mechanism.
Description of drawings of the present utility model is as follows:
Fig. 1 is a structural representation of the present utility model;
Fig. 2 is a schematic diagram of the present utility model.
Among the figure: 1. housing; 2. input channel; 3. output channel; 4. incubator; 5. blood plasma pond; 6. input; 7. blood plasma outfan; 8. blood concentration components outfan; 9. the Meng, Fei Shi managed; 10. separator; 11. heparin infusion appliance; 12. front pump; 13. adsorber; 14. sorption cycle pump; 15. bioreactor; 16. circulating pump; 17. rear pump; 18. photographic head; 19. useless blood plasma container; 20. blood exchange transfusion set.
The utility model is described in further detail below in conjunction with drawings and Examples:
As shown in Figure 1, this utility model includes housing 1 and module control circuit, it is characterized in that: as can be known in conjunction with Fig. 2, it also includes input channel 2, detaching mechanism of blood plasma, the blood plasma adsorbing mechanism, biological respinse mechanism, blood plasma output mechanism and output channel 3, incubator in the housing 1 is provided with blood plasma pond 5 for 4 li, biological respinse mechanism and blood plasma adsorbing mechanism form internal recycle with blood plasma pond 5 respectively, the blood plasma outfan 7 of the detaching mechanism of blood plasma that input 6 is communicated with input channel 2 is by the liquid pipe, the liquid pipe valve feeds blood plasma pond 5 and useless blood plasma container 19 respectively, the blood concentration components outfan 8 of detaching mechanism of blood plasma by the Meng Fei Shi pipe 9 is communicated with output channel 3, the blood plasma output mechanism that is communicated with blood plasma pond 5 passes through Meng Fei Shi and manages 9 and be communicated with output channel 3.
As shown in Figure 1, 2, detaching mechanism of blood plasma is to be made of separator 10, heparin infusion appliance 11 and the front pump 12 that is connected with module control circuit, the input 6 of detaching mechanism of blood plasma is communicated with through the inlet of front pump 12 with separator 10 by the liquid pipe, heparin infusion appliance 11 is communicated with the inlet of separator 10, the blood plasma outlet of separator 10 promptly is the blood plasma outfan 7 of detaching mechanism of blood plasma, and the blood concentration components outlet of separator promptly is the blood concentration components outfan 8 of detaching mechanism of blood plasma.
As shown in Figure 1, 2, the blood plasma adsorbing mechanism is to be made of liquid pipe, adsorber 13 and the sorption cycle pump 14 that is connected with module control circuit, after the inlet of the adsorbing mechanism that is communicated with blood plasma pond 5 was connected in series adsorber 13 and sorption cycle pump 14 mutually by the liquid pipe, its outlet was communicated with blood plasma pond 5.
As shown in Figure 1, 2, biological respinse mechanism is by the liquid pipe, places the bioreactor 15 in the incubator 4 to constitute with the circulating pump 16 that is connected with module control circuit, after the inlet of the biological respinse mechanism that is communicated with blood plasma pond 5 was connected in series bioreactor 15 and circulating pump 16 mutually by the liquid pipe, its outlet was communicated with blood plasma pond 5.
As shown in Figure 1, 2, the blood plasma output mechanism be the liquid pipe that is communicated with blood plasma pond 5 by the rear pump 17 that is connected with module control circuit afterwards with the Meng Fei Shi manage 9 and be communicated with, blood exchange transfusion set 20 is communicated with the input port of rear pump 17.
As shown in Figure 1, for the ease of observing plasma volume and blood plasma liquid level situation in the blood plasma pond 5, operate and use this device better, the side in blood plasma pond 5 is provided with the blood plasma liquid level monitoring arrangement that is connected with module control circuit.The blood plasma liquid level monitoring arrangement can be a photographic head 18.
This utility model is external artificial hepaticsupport system, does not insert in patient's body, but blood samples of patients is drawn, and after the processing through the difference in functionality effect, converges and flows back in patient's body, so repeatedly, finally reaches the effect of artificial liver support and replacement therapy.Now its operation principle can be described below in conjunction with Fig. 1,2:
Input channel 2 of the present utility model is communicated with patient's tremulous pulse or vein by puncture, output channel 3 is communicated with patient's vein by puncture, to realize the connection of bloody path.
At first, module control circuit control front pump 12 is sent into patient's blood in the separator 10, separator 10 is separated into blood samples of patients invisible and blood plasma that have toxicant and tangible blood concentration components, control liquid pipe valve, make the blood plasma that has toxicant through blood plasma outfan 7, the liquid pipe is transported in the useless blood plasma container 19 and it is abandoned, the blood concentration components is through blood concentration components outfan 8, the Meng, the Fei Shi pipe 9, output channel 3 flows back in patient's body, simultaneously, under the effect of module control circuit, by rear pump 17 and blood exchange transfusion set 20 in patient's body, to inject normal person's blood plasma with the same speed of the toxic material blood plasma of blood plasma outfan 7 elution bands, this process is carried out repeatedly, the blood plasma that has toxicant in useless blood plasma container reaches till institute's plasma volume to be processed, this is the treatment of first step artificial liver, its objective is that the blood plasma that patient's body is contained more toxicant discards, in patient's body, mend normal person's blood plasma, realize detoxifcation and purification blood.
Continuation is sent into patient's blood in the separator 10 by module control circuit control front pump 12, separator 10 is separated into blood samples of patients invisible and blood plasma that have toxicant and tangible blood concentration components, control liquid pipe valve, make the blood plasma that has toxicant through blood plasma outfan 7, the liquid pipe is transported in the blood plasma pond 5, the blood concentration components is still through blood concentration components outfan 8, the Meng, the Fei Shi pipe 9, output channel 3 flows back in patient's body, when treating that blood plasma in the blood plasma pond 5 reach a certain height, start rear pump 17, with the blood plasma in the blood plasma pond 5 through rear pump 17, the Meng, the Fei Shi pipe 9, output channel 3 to be failing back in patient's body with the same speed of the toxic material blood plasma of blood plasma outfan 7 elution bands, thereby realizes balance between patient's body inner blood and the device outside and stable circulating.
In the above-mentioned blood circulation flow process, in separator 10, inject heparin by heparin infusion appliance 11 all the time, in case hemostasis liquid solidifies in the process of circulating.
Keeping on the mobile basis of above-mentioned blood circulation, module control circuit control sorption cycle pump 14 makes the blood plasma that has toxicant in the blood plasma pond and adsorber 13 carry out high speed and circulates, utilize the active carbon in the adsorber 13 to inhale most harmful substances in the slurry of dehematizing, till the adsorbance of adsorber 13 reaches capacity, thereby realize the physical property detoxifcation to blood plasma, this is the artificial liver treatment of second step.In this process, adsorber 13 is also inhaled and have been gone in the blood plasma human body beneficial's material, and this deficiency can be remedied in bioartificial liver's treatment in the 3rd step fully.
Under definite sorption cycle pump 14 out-of-work prerequisites, module control circuit control circulating pump 16 makes the blood plasma of handling through above-mentioned detoxifcation in the blood plasma pond 5 carry out high speed with bioreactor 15 again and circulates, bioreactor 15 is hollow fiber bioreactor, its inner chamber is cultivated a large amount of highly active cultivation hepatocyte, when blood plasma passes through bioreactor 15 exocoels, carry out two-way mass exchange and exchange with highly active cultivation hepatocyte by the semipermeable membrane on the doughnut, highly active cultivation hepatocyte carries out specific picked-up to the toxicant in the blood plasma, conversion, metabolism, the large number of biological of synthesis secretion release simultaneously active substance enters blood plasma, so repeatedly, patient's blood plasma is carrying out the antidotal while for a full due in the mode of biology, replenish the large number of biological active substance of needed by human body again, thereby finished the 3rd step bioartificial liver treatment.
In sum, this utility model is as introducing blood samples of patients in external second liver, finishes the physiological function of the liver of loss of function in patient's body, Here it is mixed biologic artificial liver supporting treatment or alternative medicine by external this utility model.By therapeutical effect of the present utility model, the patient can recover by self liver regeneration, or recovers as liver transplantation through other treatment.This utility model creates conditions for above-mentioned liver regeneration or liver transplantation etc. just, races against time and chance, and be a kind of effective and requisite treatment means of excessive property, it has great importance aspect redemption liver failure patient life.
Claims (7)
1. mixed biologic artificial hepaticsupport system, include housing (1) and module control circuit, it is characterized in that: it also includes input channel (2), detaching mechanism of blood plasma, the blood plasma adsorbing mechanism, biological respinse mechanism, blood plasma output mechanism and output channel (3), incubator (4) lining in the housing (1) is provided with blood plasma pond (5), biological respinse mechanism and blood plasma adsorbing mechanism form internal recycle with blood plasma pond (5) respectively, the blood plasma outfan (7) of the detaching mechanism of blood plasma that input (6) is communicated with input channel (2) is by the liquid pipe, the liquid pipe valve feeds blood plasma pond (5) and useless blood plasma container (19) respectively, the blood concentration components outfan (8) of detaching mechanism of blood plasma is communicated with output channel (3) by Fei Shi pipe in the Meng (9), and the blood plasma output mechanism that is communicated with blood plasma pond (5) is by being communicated with output channel (3) by Fei Shi pipe in the Meng (9).
2. mixed biologic artificial hepaticsupport system as claimed in claim 1, it is characterized in that: detaching mechanism of blood plasma is by separator (10), heparin infusion appliance (11) constitutes with the front pump that is connected with module control circuit (12), the input of detaching mechanism of blood plasma (6) is communicated with through the inlet of front pump (12) with separator (10) by the liquid pipe, heparin infusion appliance (11) is communicated with the inlet of separator (10), the blood plasma outlet of separator (10) promptly is the blood plasma outfan (7) of detaching mechanism of blood plasma, and the blood concentration components outlet of separator promptly is the blood concentration components outfan (8) of detaching mechanism of blood plasma.
3. mixed biologic artificial hepaticsupport system as claimed in claim 1, it is characterized in that: the blood plasma adsorbing mechanism is to be made of liquid pipe, adsorber (13) and the sorption cycle pump (14) that is connected with module control circuit, the inlet of the adsorbing mechanism that is communicated with blood plasma pond (5) by the liquid pipe with adsorber (13) and sorption cycle pump (14) is mutual be connected in series after, its outlet is communicated with blood plasma pond (5).
4. mixed biologic artificial hepaticsupport system as claimed in claim 1, it is characterized in that: biological respinse mechanism is by the liquid pipe, places the bioreactor (15) in the incubator (4) to constitute with the circulating pump that is connected with module control circuit (16), the inlet of the biological respinse mechanism that is communicated with blood plasma pond (5) by the liquid pipe with bioreactor (15) and circulating pump (16) is mutual be connected in series after, its outlet is communicated with blood plasma pond (5).
5. mixed biologic artificial hepaticsupport system as claimed in claim 1, it is characterized in that: the liquid pipe that the blood plasma output mechanism is with blood plasma pond (5) are communicated with is communicated with Fei Shi pipe in the Meng (9) by rear pump (17) back that is connected with module control circuit, and blood exchange transfusion set (20) is communicated with the input port of rear pump (17).
6. as claim 1 or 2 or 3 or 4 or 5 described mixed biologic artificial hepaticsupport systems, it is characterized in that: the side of blood plasma pond (5) is provided with the blood plasma liquid level monitoring arrangement that is connected with module control circuit.
7. mixed biologic artificial hepaticsupport system as claimed in claim 6 is characterized in that: the blood plasma liquid level monitoring arrangement is photographic head (18).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00223561 CN2426361Y (en) | 2000-06-29 | 2000-06-29 | Mixed biologic artificial liver supporting device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00223561 CN2426361Y (en) | 2000-06-29 | 2000-06-29 | Mixed biologic artificial liver supporting device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN2426361Y true CN2426361Y (en) | 2001-04-11 |
Family
ID=33588088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00223561 Expired - Fee Related CN2426361Y (en) | 2000-06-29 | 2000-06-29 | Mixed biologic artificial liver supporting device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN2426361Y (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002087661A1 (en) * | 2001-04-28 | 2002-11-07 | Cell Biotech Limited | A compound artificial liver system and the method for using the said system |
| CN110141706A (en) * | 2019-06-14 | 2019-08-20 | 科先医疗科技(苏州)有限公司 | A kind of Biotype artificial liver circulatory support system |
-
2000
- 2000-06-29 CN CN 00223561 patent/CN2426361Y/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002087661A1 (en) * | 2001-04-28 | 2002-11-07 | Cell Biotech Limited | A compound artificial liver system and the method for using the said system |
| CN110141706A (en) * | 2019-06-14 | 2019-08-20 | 科先医疗科技(苏州)有限公司 | A kind of Biotype artificial liver circulatory support system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8096969B2 (en) | Peritoneal dialysis methods and apparatus | |
| US4243532A (en) | Blood treating system | |
| CN101732771B (en) | Cell reactor and artificial liver support system comprising same | |
| CA2129427A1 (en) | Organ support system | |
| US5976870A (en) | Artificial liver composed of a liver-slice culture apparatus | |
| US8876753B2 (en) | Peritoneal dialysis methods and apparatus | |
| CN108430529A (en) | system and method for extracorporeal blood treatment | |
| CN201123923Y (en) | Mixed type artificial liver system capable of for curing multiple-organ dysfunctional syndrome | |
| CN2638736Y (en) | Heterozygous artificial liver supporting device | |
| CN2426361Y (en) | Mixed biologic artificial liver supporting device | |
| US12011691B2 (en) | Fluid treatment method, cycle treatment device and system | |
| CN1137733C (en) | Method and equipment for externally mixed biologic artificial liver | |
| CN204521750U (en) | A kind of artificial liver and blood purification system | |
| de Francisco et al. | Hemodiafiltration with on-line endogenous reinfusion | |
| CN1814310A (en) | Disposable viral inactivating blood transfusion filting device | |
| CN2595373Y (en) | Disposable filter for virus inactivation and blood transfusion | |
| CN101455864B (en) | Mixed biology artificial liver vitro supporting device | |
| CN1383898A (en) | Composite artificial liver supporting system and its usage | |
| CN203244631U (en) | Plasma storage bag for plasma exchange, absorbing and filtering treatment | |
| CN208552666U (en) | A kind of plasma exchange dialysis adsorption system | |
| CN100337698C (en) | In vitro biologic artificial liver supporting device | |
| CN103263706A (en) | Plasma storage bag special for plasma exchange, absorption, and filtration treatment | |
| CN203417361U (en) | Square plasma storage pool special for plasma exchange adsorption filtration treatment | |
| CN2661199Y (en) | Microcarrier stirred type biological artificial liver support system | |
| JP4833443B2 (en) | How to collect hematopoietic stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |